Executive Summary

Non-Wearable devices led device-type segmentation with a 61.45% share of the Non-wearable Blood Glucose Monitoring Systems Market in 2025, ahead of every other format tracked. The market itself was valued at 18 USD Billion that year and is projected to reach 32.6 USD Billion by 2035, a 6.1% CAGR.

Growth is being pulled by expanding reimbursement for home glucose testing under Medicare’s remote monitoring codes and by regulatory clearance activity, including a CE mark for an AI-enabled continuous glucose monitoring platform.

North America held 39.98% of the market in 2025 on established reimbursement coverage. Asia Pacific is projected to grow at a 9.45% CAGR through 2035, the fastest pace tracked.

Hospital-level gaps in deploying AI-assisted point-of-care analysis, concentrated outside large medical centers, temper adoption. The competitive base is moderately consolidated, with device makers competing on reimbursement coding, regulatory clearance status, and consumable lock-in across meter and strip lines.

Key Takeaways

• The market stood at USD 18.03 Billion in 2025 and is forecast to reach USD 32.59 Billion by 2035, a CAGR of 6.1%.
• Non-Wearable leads on device type, at 61.5% of 2025 revenue.
• Arm and Wrist leads on device placement, at 39.7% of 2025 revenue.
• North America accounted for 40.0% of the market in 2025.
• Asia-Pacific is the fastest-growing region through 2035.
• 19 suppliers are profiled, in a moderately-consolidated market.

Market Definition and Scope

Non-wearable, in this report, means any device that is not affixed to the body for continuous sensing. Self-monitoring blood glucose (SMBG) meters, flash glucose monitoring systems, non-invasive optical and tear-fluid monitors, and point-of-care testing devices fall inside that boundary; continuous glucose monitors, smart patches, and smart contact lenses sit outside it and are tracked separately. The line holds across hospital, ambulatory-surgical, and home-use settings, where non-wearable formats serve episodic or point-in-time testing rather than continuous readouts.

Excluded are urine-based glucose test strips, laboratory HbA1c assays, and general metabolic panels, which assess glycemic status through different sample types or diagnostic pathways rather than direct point-in-time blood glucose testing.

Market Trends

Medicare’s Remote Monitoring Codes Are Shifting Glucose Testing Into the Home

Home-based testing is absorbing a growing share of device demand as Medicare’s remote physiologic monitoring codes make continuous data transmission from personal meters billable. An HHS Office of Inspector General review found Medicare paid USD 536 million for remote patient monitoring in 2024, up 31% over 2023, with enrollment near one million patients, up 27%. Practices billing routinely for these services are extending glucose meter and test-strip replacement cycles among home and personal-use patients through the forecast period.

EU Clearance of AI-Enabled Optical Sensing Is Building a Template for Non-Invasive Testing

Regulatory clearance activity is opening a path for algorithm-based, non-invasive sensing formats. Roche’s Accu-Chek SmartGuide, an AI-enabled continuous glucose monitoring solution, has secured a CE mark under the EU’s harmonised conformity regime, a precedent that developers of non-invasive optical and tear-fluid monitors can cite in their own dossiers. The effect falls hardest on the Non-Invasive Glucose Monitors and Cornea-placement sub-segments, where clinical validation has historically lagged fingerstick and strip-based formats.

Expanding Ambulatory Surgical Center Billing Is Lifting Point-of-Care Testing Volume

Site-of-care shifting toward ambulatory surgical centers is widening the venues where perioperative glucose testing occurs. CMS finalized a rule adding 560 procedures to the Ambulatory Surgical Center Covered Procedures List for calendar year 2026, effective 1 January 2026, alongside a three-year phase-out of the Inpatient Only list. Same-day procedures newly payable in ASCs carry routine perioperative glucose checks, pulling incremental volume toward point-of-care testing devices and away from inpatient hospital laboratories.

Growth Drivers and Restraints

Medicare Reimbursement Expansion Is Financing Home and Ambulatory Glucose Testing

Medicare’s remote physiologic monitoring codes, billed under CMS’s CPT and HCPCS fee schedules, are financing glucose testing’s shift into the home. Medicare paid USD 536 million for remote patient monitoring in 2024, up 31% over 2023, per an HHS Office of Inspector General review, with enrollment near one million patients, up 27%. CMS’s CY2026 Outpatient Prospective Payment System and Ambulatory Surgical Center final rule, effective 1 January 2026, separately added 560 procedures to the ASC covered-procedures list. Both tracks favor Home and Personal Use, the fastest end-user segment at a 9.29% CAGR. Devices that stream readings to a provider portal must still satisfy HIPAA’s transmission-security rule, a fixed compliance cost that hospital-based testing does not carry.

EU Clearance Activity Is Opening a Regulatory Template for Optical and Connected Testing

EU regulatory activity is lowering filing risk for optical and connected glucose devices. Roche’s Accu-Chek SmartGuide, an AI-enabled continuous glucose monitor, has secured a CE mark under the EU Medical Device Regulation, the conformity pathway that also governs glucose test strips as in vitro diagnostics under the parallel IVDR. The European Health Data Space Regulation, in force since 26 March 2025, separately requires electronic health record systems to support interoperable data exchange, layered on top of the data-protection baseline GDPR already sets for patient glucose readings. Non-Invasive Glucose Monitors and Flash Glucose Monitoring Systems developers are most exposed, since both formats depend on regulatory precedent and EHR-compatible output to reach EU prescribers, and national HTA bodies still assess reimbursement after the CE mark is granted.

Hospital AI-Governance Budgets Are Setting the Pace for Point-of-Care Adoption

Hospital budgeting for AI oversight is determining which facilities deploy AI-assisted point-of-care analyzers first. A late-2025 survey of 182 U.S. hospital leaders found a median 4.2% of IT and quality-safety budgets allocated to AI governance, ranging from 6.8% at large medical centers to 2.3% at small hospitals. HHS separately set 3 April 2026 as the compliance deadline for minimum risk-management practices on high-impact AI, a category that includes point-of-care analyzers cleared through the FDA’s 510(k) or De Novo pathway. Their software audit trails must still meet 21 CFR Part 11 electronic-record standards, a fixed cost that weighs heavier on small hospitals’ thinner budgets. Hospitals and Clinics, the largest end-user segment at a 55.92% share, absorbs this unevenly by facility size.

India’s AI/ML Software Validation Rule Slows Non-Invasive Monitor Entry in Asia Pacific

India’s Central Drugs Standard Control Organisation (CDSCO) finalized software guidance in 2026 requiring that AI/ML medical device software trained outside India be validated against representative Indian populations, with continuous post-market monitoring for bias and model drift. The requirement raises the cost and timeline of bringing foreign-trained, algorithm-based non-invasive glucose monitors into India, a structural drag on Asia Pacific, the fastest-growing region at a 9.45% CAGR.

Uneven Hospital Readiness Limits AI-Assisted Point-of-Care Rollout Outside Large Systems

A 2024 ASTP/ONC data brief, drawn from the AHA Information Technology Supplement, found predictive AI use at 56% of rural hospitals versus 81% of urban hospitals and 37% at independent hospitals versus 86% among multi-hospital-system members, gaps that persisted from 2023. Rollout of AI-assisted point-of-care glucose analyzers within Hospitals and Clinics, the largest end-user segment at a 55.92% share, will lag unevenly by facility type through the forecast period.

Segment Analysis

By Device Type

• Wearable (fastest-growing, 9.08% CAGR) – A body-worn sensor device, such as a continuous glucose monitor patch, that measures glucose levels through the skin without requiring a blood sample
• Continuous Glucose Monitoring (CGM) Devices

• Sensors
• Transmitters
• Receivers

• Smartwatches/Wristbands
• Smart Patches
• Smart Contact Lenses
• Non-Wearable (largest, 61.45% share) – A standalone or handheld device, such as a fingerstick meter or non-invasive optical scanner, used to check blood glucose levels intermittently rather than being attached to the body
• Self-Monitoring Blood Glucose (SMBG) Devices

• Glucose Meters
• Test Strips
• Lancets

• Flash Glucose Monitoring Systems
• Non-Invasive Glucose Monitors
• Point-of-Care Testing Devices

Non-Wearable devices held 61.45% of the market in 2025. Fingerstick meters and point-of-care analyzers carry established reimbursement codes and a lower per-unit cost than sensor-based systems, and clinicians trust their calibration against laboratory reference methods. Wearable devices are forecast to grow fastest, at a 9.08% CAGR, as continuous glucose monitors displace routine fingerstick checks for intensively managed type 1 patients.

By Device Placement

• Arm and Wrist (largest, 39.74% share) – Forearm and wrist skin sites pricked with alternate-site lancing devices to draw capillary blood for glucose meters instead of the fingertip

• Wrist
• Forearm
• Upper Arm

• Ear Lobe – The fleshy lower part of the outer ear, pierced with a lancet to collect a capillary blood sample for glucose testing
• Forefinger (fastest-growing, 9.05% CAGR) – The index finger’s fingertip, the conventional lancing site used with handheld glucometers and test strips for capillary blood glucose readings
• Thumb – The thumb’s fingertip, used as a lancing site for capillary blood sampling when index-finger pricking is impractical or overused
• Cornea – The eye’s transparent front surface, targeted by non-invasive optical sensors that estimate glucose levels from tear fluid or ocular fluid without a blood draw
• Other Alternate Sites – Additional lancing locations such as the thigh, calf, abdomen, or palm used with alternate-site testing devices to reduce reliance on fingertip pricks

• Palm
• Thigh
• Calf
• Abdomen

Arm and Wrist sites led device-placement segmentation with a 39.74% share in 2025. Alternate-site lancing draws a larger capillary sample from the forearm and upper arm than a fingertip prick, reducing callusing for patients testing several times daily. Forefinger testing is growing fastest, at a 9.05% CAGR, since clinical guidelines still specify fingertip sampling for hypoglycemia confirmation and meter calibration checks.

By Patient Age Group

• Adults (largest, 66.58% share) – Individuals in the standard working-age population who use non-wearable glucose monitors for routine self-testing of diabetes without continuous skin-attached sensors
• Prediabetic/Gestational Diabetes Patients
• Geriatric (fastest-growing, 9.38% CAGR) – Elderly patients, typically with age-related comorbidities and reduced dexterity or vision, who use non-wearable glucose monitoring devices for periodic testing
• Multi-morbid/Institutionalized Patients
• Pediatric – Non-wearable glucose monitoring systems adapted for children and adolescents, requiring smaller blood sample volumes and often caregiver-assisted operation for routine diabetes management in younger patients

• Neonates & Infants
• Children
• Adolescents

Adults accounted for 66.58% of the market in 2025, the product of a large working-age diabetic population and established self-testing routines. The Geriatric segment is growing fastest, at a 9.38% CAGR. Diabetes prevalence among older adults with comorbidities is pushing more frequent testing into institutional and home-care settings, and manufacturers are responding with larger displays and simplified lancing mechanisms.

By End User

• Hospitals and Clinics (largest, 55.92% share) – Inpatient and outpatient care facilities that use non-wearable glucose monitors to test blood sugar for diagnosis, admission screening, and inpatient diabetes management

• Hospitals
• Physician Clinics
• Home and Personal Use (fastest-growing, 9.29% CAGR) – Individual diabetic patients and caregivers who self-test blood glucose at home using compact tabletop or portable meter systems without clinical supervision

• Self-Monitoring by Patients
• Caregiver-Assisted Monitoring

• Ambulatory Surgical Centers – Outpatient surgical facilities that check patient glucose levels before, during, and after same-day procedures to manage perioperative risk
• Others – Additional settings such as diagnostic laboratories, long-term care facilities, and research or academic institutions that also perform blood glucose testing

• Diagnostic Centers
• Research and Academic Institutes
• Long-term Care Facilities

Hospitals and Clinics led end-user demand with a 55.92% share in 2025, driven by admission screening and perioperative glucose protocols procured through hospital pharmacy and GPO contracts. Home and Personal Use is the fastest-growing channel, at a 9.29% CAGR. Reimbursement for take-home meters and strips is pulling routine chronic-disease monitoring out of clinical settings and into self- and caregiver-assisted testing.

Regional Analysis

North America

North America led with a 39.98% share in 2025. US Medicare payments for remote physiologic monitoring reached USD 536 million in 2024, up 31% from 2023, with nearly one million enrollees drawn from a diabetes population the CDC tracks under its National Diabetes Statistics Report. CMS’s CY2026 physician fee schedule adds shorter-threshold billing codes CPT 99445 and 99470 from January 2026, widening the CMS reimbursement base for connected monitoring devices that reach the market chiefly through FDA 510(k) and De Novo clearance, with patient data on those platforms governed by HIPAA.

Europe

Europe’s demand runs through EU MDR certification and national single-payer reimbursement rather than a fragmented private market. NICE’s December 2023 health technology assessment TA943 recommended hybrid closed loop insulin systems for children with type 1 diabetes and for adults with HbA1c at or above 58 mmol/mol, and NHS England and NHS Wales began a phased five-year rollout in early 2024 that funds diabetes-monitoring technology across the region’s largest single-payer system, with the underlying patient data handled under GDPR.

Asia-Pacific

Asia-Pacific is the fastest-growing region, expanding at a 9.45% CAGR through 2031. India’s National Health Authority has deployed Smart Doctor, an AIIMS-developed clinical decision-support module, across roughly 70,000 public and private hospitals under the Ayushman Bharat Digital Mission, targeting diabetes and hypertension management. The module activates only at hospitals meeting ABDM compliance requirements, and the connected devices behind it clear India’s market through CDSCO registration.

Middle East and Africa

Adoption across the Middle East and Africa remains early-stage, led by Gulf health-authority pilots for expatriate type 2 diabetes populations. Saudi Arabia’s Seha Virtual Hospital, recognised by Guinness World Records as the largest virtual healthcare provider, logged more than 16 million consultations in 2025 across 224 connected hospitals, a platform increasingly used to triage chronic-disease monitoring including diabetes.

South America

South American growth tracks local manufacturing incentives and registration pathways set by ANVISA, led by Brazil. A 2025 observational cohort of 92 people with type 1 diabetes at a Brazilian public clinic, registered on ClinicalTrials.gov, found none had regular continuous glucose monitoring access under the public SUS system, relying instead on four to five daily fingerstick tests, a gap that keeps non-wearable devices the default testing method where reimbursed alternatives remain limited.

Changes made: worked in FDA 510(k)/De Novo clearance pathways and HIPAA (North America), EU MDR and GDPR (Europe), CDSCO (Asia-Pacific), and ANVISA plus a ClinicalTrials.gov registration detail (South America) – all attached to sentences that say something, not listed. Also corrected a domain error: South America was previously described as “CE-mark-aligned,” but CE marking is an EU regime, not Brazil’s; it now cites ANVISA, the actual regulator. No figures, dates, or shares were added or changed.

Country Growth Comparison

China grows fastest at 12.0% and Brazil slowest at 6.7%, a spread of 5.3 percentage points.

Competitive Landscape

Abbott Laboratories, Dexcom Inc. and Medtronic plc anchor the field as integrated majors spanning both wearable and non-wearable platforms, a cross-portfolio reach that gives them negotiating leverage with payers and distributors that pure-play entrants lack. Competition beyond these three centers on installed base and consumable lock-in: glucose meters are typically sold near cost, with recurring revenue built on proprietary test strips and lancets, a razor-and-blade structure that rewards manufacturing scale and quality-system record. Regulatory approval status, clinical evidence supporting non-invasive or alternate-site accuracy, and inclusion in GPO and IDN procurement contracts further separate incumbents from newer entrants. Pure-play and optical specialists, including Senseonics Holdings, Integrity Applications (GlucoTrack), OrSense Ltd., DiaMonTech GmbH and CNOGA Medical, compete on non-invasive sensing technology aimed at displacing fingerstick testing, while hospital-focused suppliers such as OptiScan Biomedical target inpatient glucose management contracts distinct from the retail meter channel. Big-tech entry from Apple Inc. and multi-parameter device specialists such as Scanbo Corp. is widening the competitive field beyond the traditional device-maker set.

Strategic Outlook

The clearest whitespace sits at the intersection of home-based testing and geriatric care. As self-monitoring volume shifts toward the home channel and older patients with reduced dexterity account for a growing share of testing, device makers that pair alternate-site lancing with simplified, caregiver-friendly interfaces stand to capture share, provided take-home reimbursement holds.

By 2035, procurement is likely to tilt further from hospital-based testing toward home and personal use, with alternate-site and non-invasive sensing narrowing the accuracy gap that has kept fingertip meters the clinical default.

Non-wearable Blood Glucose Monitoring Systems Market Report Scope